Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.

Asthma is a chronic inflammatory lung disease characterized by repeated episodes of wheezing, breathlessness, coughing and chest tightness. Some patients with asthma have inadequately controlled disease despite treatment with an inhaled corticosteroid (ICS) and a long-acting ß₂ agonist (LABA). The addition of a long-acting muscarinic antagonist (LAMA) may provide further benefit, but has traditionally required the use of two separate inhalers. Indacaterol/glycopyrronium/mometasone (Enerzair^® Breezhaler^®) is the first fixed-dose LABA/LAMA/ICS combination for asthma therapy. It is administered once daily using a single inhaler. There is also an optional digital sensor that attaches to the base of the device to collect data on the use of the inhaler by the patient. Indacaterol/glycopyrronium/mometasone improved lung function to a greater extent than LABA/ICS combinations in adult patients with inadequately controlled asthma who had experienced one or more exacerbations in the previous year. Indacaterol/glycopyrronium/mometasone was generally well tolerated. The most common adverse events were respiratory-related. Combination therapy with indacaterol/glycopyrronium/mometasone is a valuable, convenient option for the maintenance treatment of asthma.